3H-morphine-6β-glucuronide binding in brain membranes and an MOR-1- transfected cell line

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 3, 1997, Pages 1291-1297

  Brown, George P ^a   Yang, Ke ^a   Ouerfelli, Ouathek ^a   Standifer, Kelly M ^b   Byrd, David ^a   Pasternak, Gavril W ^a,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c Department of Neurology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPRENORPHINE; DRUG RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MORPHINE; MORPHINE 6 GLUCURONIDE; MORPHINE DERIVATIVE; MU OPIATE RECEPTOR; NALOXONE; MORPHINE-6-GLUCURONIDE;

ANALGESIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CATTLE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BINDING COMPETITION; BINDING SITE; BRAIN; GENETIC TRANSFECTION; GENETICS; HAMSTER; METABOLISM; PHYSIOLOGY;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CHO CELLS; CRICETINAE; MORPHINE DERIVATIVES; RECEPTORS, OPIOID, MU; TRANSFECTION;

EID: 0030610661     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. ABBOTT, F. V. AND PALMOUR, R. M.: Morphine-6-glucuronide: Analgesic effects and receptor binding profile in rats. Life Sci. 43: 1685-1695, 1988.
2. ADAMS, J. U., CHEN, X., DERIEL, J. K., ADLER, M. W. AND LIU-CHEN, L.-Y.: Intracerebroventricular treatment with an antisense oligodeoxynucleotide to kappa-opioid receptors inhibited kappa-agonist-induced analgesia in rats Brain Res. 667: 129-132, 1994.
3. BENYHE, S.: Morphine: New aspects in the study of an ancient compound. Life Sci. 55: 969-979, 1994.
4. 4]deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor. Life Sci. 55: 37-43, 1994.
5. BILSKY, E. J., BERNSTEIN, R. N., HRUBY, V. J., ROTHMAN, R. B., LAI, J. AND PORRECA, F.: Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated 'knock-down' of opioid receptors in vivo. J. Pharmacol. Exp. Ther. 277: 491-501, 1996.
6. CHEN, X. H., ADAMS, J. U., GELLER, E. B., DERIEL, J. K., ADLER, M. W. AND LIU-CHEN, L.-Y.: An antisense oligodeoxynucleotide to μ-opioid receptors inhibits μ-opioid receptor agonist-induced analgesia in rats. Eur. J. Pharmacol. 275: 105-108, 1995.
7. 3-opioid receptors in the SH-SY5Y human neuroblastoma cell line. J. Neurochem. 65: 170-175, 1995.
8. CHIEN, C.-C., BROWN, G., PAN, Y.-X. AND PASTERNAK, G. W.: Blockade of U50,488H analgesia by antisense oligodeoxynucleotides to a kappa-opioid receptor. Eur. J. Pharmacol. 253: R7-R8, 1994.
9. CHIEN, C. C. AND PASTERNAK, G. W.: (-)-Pentazocine analgesia in mice: Interactions with a σ receptor system. Eur. J. Pharmacol. 294: 303-308, 1995.
10. 1 binding assay. Mol. Pharmacol. 34: 308-317, 1988.
11. 3 subtype. J. Pharmacol. Exp. Ther. 251: 461-468, 1989.
12. KOLESNIKOV, Y. A., JAIN, S., WILSON, R. AND PASTERNAK, G. W.: Pheripheral morphine analgesia: Synergy with central sites and a target of morphine tolerance. J. Pharmacol. Exp. Ther. 279: 502-506 1996.
13. 2-agonist antinociception. Neuroreport 5: 1049-1052, 1994.
14. LAI, J., BILSKY, E. J. AND PORRECA, F.: Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands. J. Recept. Res. 15:643-650, 1995.
15. LAI, J., RIEDL, M., STONE, L. S., ARVIDSSON, U., BILSKY, E. J., WILCOX, G. L., ELDE, R. AND PORBECA, F.: Immunofluorescence analysis of antisense oligodeoxynucleotide-mediated 'knock-down' of the mouse δ opioid receptor in vitro and in vivo. Neurosci. Lett. 213: 205-208, 1996.
16. LEVENTHAL, L., BODNAR, R. J., COLE, J. L., ROSSI, G. C., PAN, Y. X. AND PASTERNAK, G. W.: Antisense oligodeoxynucleotides against the MOR-1 clone alter weight and ingestive responses in rats. Brain Res 719: 78-84, 1996.
17. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RUNDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
18. 2 opioid binding in the mouse central nervous system. Brain Res. 360: 117-129, 1985.
19. OSBORNE, R., JOEL, S., TREW, D. AND SLEVIN, M.: Morphine and metabolite behaviour after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin. Pharmacol. Ther. 47: 12-19, 1990.
20. OUERFELLI, O., BROWN, G. P., YANG, K., WATANABE, K. A. AND PASTERNAK, G. W.: A new and practical synthesis of radiolabeled morphine-6β-glucuronide. Submitted 1997.
21. 3-related opioid receptor. Mol. Pharmacol. 47: 1180-1188, 1995.
22. 3-related opioid receptor using antisense oligodeoxynucleotides. Regul. Pept. 54:217-218, 1994.
23. PASTERNAK, G. W., BODNAR, R. J., CLARK, J. A. AND INTURRISI, C. E.: Morphine-6-glucuronide, a potent mu agonist. Life Sci. 41: 2845-2849, 1987.
24. PASTERNAK, G. W. AND STANDIFER, K. M.: Mapping of opioid receptors using antisense oligodeoxynucleotides: Correlating their molecular biology and pharmacology. Trends Pharmacol. Sci. 16: 344-350, 1995.
25. PAUL, D., STANDIFER, K. M., INTURRISI, C. E. AND PASTERNAK, G. W.: Pharmacological characterization of morphine-6β-glucuronide, a very potent morphine metabolite. J. Pharmacol. Exp. Ther. 251: 477-483, 1989.
26. PERT, C. B., PASTERNAK, G. W. AND SNYDER, S. H.: Opiate agonists and antagonists discriminated by receptor binding in brain. Science 182: 1359-1361, 1973.
27. RAFFA, R. B., MARTINEZ, R. P. AND CONNELLY, C. D.: G-protein antisense oligodeoxyribonucleotides and μ-opioid supraspinal antinociception. Eur. J. Pharmacol. 258: R5-R7, 1994.
28. ROSSI, G. C., PAN, Y.-X., CHENG, J. AND PASTERNAK, G. W.: Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci. 54: PL375-379, 1994.
29. ROSSI, G. C., PAN, Y.-X., BROWN, G. P. AND PASTERNAK, G. W.: Antisense mapping the MOR-1 opioid receptor: Evidence for alternative splicing and a novel morphine-6β-glucuronide receptor. FEBS Lett. 368: 192-196, 1995a.
30. ROSSI, G. C., STANDIFER, K. M. AND PASTERNAK, G. W.: Differential blockade of morphine and morphine-6β-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein α subunits in rats. Neurosci. Lett. 198: 99-102, 1995b.
31. ROSSI, G. C., BROWN, G. P., LEVENTHAL, L., YANG, K. AND PASTERNAK, G. W.: Morphine-6β-glucuronide receptors: A potential site of heroin action. Neurosci. Lett. 216: 1-4, 1996.
32. ROSSI, G. C., LEVENTHAL, L., PAN, Y. X., COLE, J., S. U., W., BODNAR, R. J. AND PASTERNAK, G. W.: Antisense mapping MOR-1 in the rat: Distinguishing between morphine and morphine-6β-glucuronide antinociception. J. Pharmacol. Exp. Ther. 281: 109-114, 1996.
33. SANCHEZ-BLAZQUEZ, P., GARCIA-ESPANA, A. AND GARZON, J.: In vivo injection of antisense oligodeoxynucleotides to Gα subunits and supraspinal analgesia evoked by mu and delta opioid agonists. J. Pharmacol. Exp. Ther. 275: 1590-1596, 1995.
34. SHIMOMURA, K., KAMATA, O., UEKI, S., IDA, S., OGURI, K., YOSHIMURA, H. AND TSUKAMOTO, H.: Analgesic effect of morphine glucuronides. Tohoku J. Exp. Med. 105: 45-52, 1971.
35. SNYDER, S. H., PERT, C. B. AND PASTERNAK, G. W.: The opiate receptor. Ann. Int. Med. 81: 534-540, 1974.
36. 3 opioid receptors expressed in BE(2)-C: Neuroblastoma cells. J. Pharmacol. Exp. Ther. 270: 1246-1255, 1994a.
37. STANDIFER, K. M., CHIEN, C.-C., WAHLESTEDT, C., BROWN, G. P. AND PASTERNAK, G. W.: Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron 12: 805-810, 1994b.
38. STANDIFER, K. M., ROSSI, G. C. AND PASTERNAK, G. W.: Differential blockade of opioid analgesia fay antisense oligodeoxynucleotides directed against various G-protein a subunits. Mol. Pharmacol. 50: 293-298, 1996.
39. SULLIVAN, A. F., MCQUAY, H. J., BAILEY, D. AND DICKENSON, A. H.: The spinal antinociceptive actions of morphine metabolites, morphine-6β-glucuronide and normorphine in the rat. Brain Res. 482: 219-224, 1989.
40. TISEO, P. J., THALER, H. T., LAPIN, J., INTURRISI, C. E., PORTENOY, R. K. AND FOLEY, K. M.: Morphine-6-glucuronide concentrations and opioid-related side effects: A survey in cancer patients. Pain 61: 47-54, 1995.
41. TSENG, L. F., COLLINS, K. A. AND KAMPINE, J. P.: Antisense oligodeoxynucleotide to a δ-opioid receptor selectively blocks the spinal antinociception induced by δ-, but not μ-or κ-opioid receptor agonists in the mouse. Eur. J. Pharmacol. 258: R1-R3, 1994.
42. YOSHIMURA, H., IDA, S., OGURI, K. AND TSUKAMOTO, H.: Biochemical basis for analgesic activity of morphine-6β-glucuronide. I: Penetration of morphine-6β-glucuronide in the brain of rats. Biochem. Pharmacol. 22: 1423-1430, 1973.